Current Long-Term Pharmacotherapies for the Management of Obesity

  • Kim, Bo-Yeon
  • Kang, Seon Mee
  • Kang, Jee-Hyun
  • Kim, Kyoung Kon
  • Kim, Bomtaeck
  • ... Kim, Yang-Hyun
  • 외 13명
Citations

WEB OF SCIENCE

23
Citations

SCOPUS

29

초록

Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index >= 25 kg/m(2). Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.

키워드

ObesityOrlistatLorcaserinLiraglutideNaltrexone/bupropion extended-releasePhentermine/topiramate extended-releaseCONTROLLED-RELEASE PHENTERMINE/TOPIRAMATEWEIGHT-LOSSCONTROLLED-TRIALOVERWEIGHT ADULTSRISK-FACTORS3.0 MGLIRAGLUTIDELORCASERINNALTREXONEASSOCIATION
제목
Current Long-Term Pharmacotherapies for the Management of Obesity
저자
Kim, Bo-YeonKang, Seon MeeKang, Jee-HyunKim, Kyoung KonKim, BomtaeckKim, Seung JunKim, Yang-HyunKim, Jung-HwanKim, Jae HyunNam, Ga EunPark, Ji YeonSon, Jang WonShin, Hye-JungOh, Tae JungLee, HyugJeon, Hyug Eon-JuChung, SochungHong, Yong HeeKim, Chong Hwa
DOI
10.7570/jomes20010
발행일
2020-06
유형
Review
저널명
Journal of Obesity & Metabolic Syndrome
29
2
페이지
99 ~ 109